The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 7 rounds in the feed, most often at Series B and in Healthtech.
Corporate venture armlabcorp.comRounds from 2023-09-27 to 2026-09-15
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Evvy Evvy sells an at-home vaginal microbiome test and a clinical care platform that treats the conditions it finds. | Series B Verified against 1 of 14 sources | $40M | 2026-09-15 | [ PART ] |
Ultrahuman Ultrahuman sells health tracking devices and services, including continuous glucose monitors and performance analytics, primarily for health-conscious consumers. | Funding round |
| $65M |
| 2026-09-03 |
| [ PART ] |
N-Power Medicine A biotech infrastructure company for oncology trials | Series B Verified against 3 sources | $32M | 2026-09-01 | [ PART ] |
PreciseDx A digital pathology platform that uses AI to assess breast cancer risk | Funding round Developing, 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $11M | 2025-06-18 | [ PART ] |
Teal Health A women’s health company on a mission to eliminate cervical cancer by making screening accessible, comfortable, and accurate | Seed ext. Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $10M | 2025-01-16 | [ PART ] |
PreciseDx A digital pathology platform that uses AI to assess breast cancer risk | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $20.7M | 2024-08-21 | [ PART ] |
Evvy Evvy sells an at-home vaginal microbiome test and a clinical care platform that treats the conditions it finds. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $14M | 2023-09-27 | [ PART ] |